Large language models auto-profile conscious awareness changes under psychedelic drug effects
Danilo Bzdok, Robin Carhart-Harris, Chloe Savignac, Gregory Bell, Steven Laureys
Research Square August 8, 2024 DOI: 10.21203/rs.3.rs-4670805/v1
Summary
AI-generated from the abstractLarge language models can design, annotate, and evaluate experience dimensions from psychedelic reports, producing over 2 million automatic ratings that discriminate the unique mental effects of 30 psychoactive substances. This approach offers a bottom-up complement to legacy questionnaires for measuring changes in subjective awareness.
Study at a glance
| Characteristics | Methodological paper Peer reviewed |
|---|---|
| Keywords | Ai consciousness mapping Psychedelic research Subjective experience Therapeutic potential |
| Citations | 3 |
| Key finding | Large language models can robustly discriminate the unique mental effects of 30 psychoactive substances through automatic scoring of experience dimensions. |
Abstract
Abstract Psychedelic experiences open a colorful view into drug-induced changes in conscious awareness. Small-sample studies on psychedelic drug action have gained traction in recent years. Yet, today’s means for measuring changes in subjective experience are mostly limited to legacy questionnaires of pre-assumed relevance, which could be complemented by bottom-up explorations of semantic facets that underlie experience reports. Here, we show how to harness large language models (LLMs) to i) design from scratch, ii) annotate at scale, and iii) evaluate with rigor a vast portfolio of experience dimensions during psychoactive drug influence, yielding > 2 million automatic dimension ratings that would otherwise have been done by hand. Investigator-independent LLM scoring of these drug effects on the human mind alone allowed to robustly discriminate the unique mental effects of 30 psychoactive substances. Successful knowledge integration of how psychedelics mediate shifts in subjective awareness will be an unavoidable milestone towards charting the full drug design space.